NL0010273215 (NL0010273215)
Quantitative Summary
DeterministicFinancial health metrics are strong: Piotroski 8/9, Altman Z 11.6 (above 3.0 safe zone threshold). DCF fair value of $688 implies 45% downside based on model assumptions.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe capital allocation efficiency is exceptionally robust, evidenced by a return on invested capital of 34.6% that significantly outpaces the weighted average cost of capital at 13.2%, generating a spread of +21.4%. This high ROIC is primarily driven by superior operational leverage rather than financial engineering or margin compression, as indicated by strong profitability metrics including net margins of 29.4% and gross margins near 53%. The firm's fundamental stability is further corroborated by an Altman Z-Score of 11.6, signaling negligible bankruptcy risk, while a Piotroski F-Score of 8/9 reflects consistent financial strength with only minor deterioration in quality over the assessment period. Additionally, the Beneish M-Score of -2.84 suggests earnings are highly credible and unlikely to be manipulated by management.
Despite these operational strengths, current valuation metrics indicate significant compression relative to historical norms and intrinsic value models. The stock trades at a forward P/E of 51.3x, which represents a 70% premium over its five-year average of 30.1x, suggesting the market is pricing in aggressive future expansion rather than current earnings power. This valuation disconnect is reinforced by discounted cash flow analysis, which implies fair value at $688 and identifies an upside potential of -45.4%, indicating a substantial discount to the price paid for anticipated free cash flow growth rates averaging 24.5% over the next decade. The market appears willing to sustain this premium only if revenue can continue expanding at 15.6% year-over-year without margin erosion.
Risk-adjusted performance data reveals a nuanced picture where high absolute returns coexist with specific factor exposures that may limit long-term compounding potential under certain regime shifts. While the Fama-French alpha of 14.56% annually demonstrates strong stock-specific outperformance, this comes at the cost of significant exposure to growth factors, highlighted by a value factor (HML) of -0.321. This negative tilt suggests vulnerability if market conditions rotate toward value-oriented assets or if growth expectations normalize. Conversely, the profitability factor score remains neutral at 0.034, indicating that while high-quality earnings are present, they do not currently provide an additional premium in multi-factor models beyond what is already captured by valuation and alpha metrics.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
Interactive5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.
The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 16% YoY revenue.
Sensitivity Matrix
| TG ↓ / WACC → | 11.2% | 13.2% | 15.2% |
|---|---|---|---|
| 2% | $792 | $642 | $537 |
| 3% | $867 | $688 | $568 |
| 4% | $962 | $743 | $603 |
Center = base case. Green = >10% upside, Red = >10% downside vs $1394.00.
Pre-computed DCF: WACC=13.2%, terminal growth 3%. Fair value $688 (-45.4%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Dividend History
| Date | Amount | Change |
|---|---|---|
| 2026-04-24 | $2.7000 | +68.8% |
| 2026-02-09 | $1.6000 | 0.0% |
| 2025-10-28 | $1.6000 | 0.0% |
| 2025-07-28 | $1.6000 | -13.0% |
| 2025-04-25 | $1.8400 | +21.1% |
| 2025-02-10 | $1.5200 | 0.0% |
| 2024-10-29 | $1.5200 | 0.0% |
| 2024-07-29 | $1.5200 | -13.1% |
| 2024-04-26 | $1.7500 | +20.7% |
| 2024-02-05 | $1.4500 | 0.0% |
| 2023-11-01 | $1.4500 | 0.0% |
| 2023-08-01 | $1.4500 | -14.2% |
Dividend and split data from SEC filings and market data. Amounts are per share, not adjusted for splits. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like EFA or IEFA, the fund manager is mechanically forced to buy or sell NL0010273215 shares regardless of NL0010273215's individual fundamentals. We estimate $7.6B of passive capital is structurally linked to NL0010273215 through 6 tracked ETFs. This substantial passive exposure means that ETF inflows and outflows — not company fundamentals — can dominate daily volume on this stock.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 6 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in NL0010273215 to visualize passive redemption contagion across ETFs and collateral stocks.
If NL0010273215 (NL0010273215) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Roche Holding AG (CH0012032048) as the most exposed collateral stock, sharing 5 ETFs with NL0010273215. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 6 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
NL0010273215 Ownership Dynamics
Passive funds hold 1 in every 70 NL0010273215 shares, reducing daily market volatility.
NL0010273215 (NL0010273215) exerts measurable gravity on the passive index market, currently representing 2.6% of the iShares MSCI EAFE ETF (EFA) and 2.2% of the iShares Core MSCI EAFE ETF (IEFA). Across 6 tracked ETFs, approximately 6M shares (1.4% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.
ETFs with Highest NL0010273215 Exposure
Float lock-up computed from 6 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
NL0010273215 Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for NL0010273215 over the past year sits near $649.81 (13% of 252-day volume). The current price of $1394.00 trades 114.5% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (13% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
NL0010273215 Capital Efficiency
How efficiently does NL0010273215 convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
NL0010273215 converts 88% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 21.4% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| USN070592100 | 0.691 | 0.830 | Moderate |
| ASML | 0.691 | 0.830 | Moderate |
| CH0012221716 | 0.604 | 0.661 | Moderate |
| LRCX | 0.512 | 0.654 | Moderate |
| AMAT | 0.509 | 0.659 | Moderate |
| KLAC | 0.480 | 0.591 | Moderate |
| TSM | 0.456 | 0.590 | Moderate |
| MU | 0.377 | 0.469 | Moderate |
| GLW | 0.366 | 0.508 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare NL0010273215 to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-01.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.